

Linda L Carpenter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7013673/publications.pdf>

Version: 2024-02-01

129
papers

10,302
citations

57758

44
h-index

34986

98
g-index

132
all docs

132
docs citations

132
times ranked

10577
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. <i>Clinical Neurophysiology</i> , 2021, 132, 269-306.	1.5	553
2	Decreased Adrenocorticotrophic Hormone and Cortisol Responses to Stress in Healthy Adults Reporting Significant Childhood Maltreatment. <i>Biological Psychiatry</i> , 2007, 62, 1080-1087.	1.3	458
3	Childhood Adversity and Epigenetic Modulation of the Leukocyte Glucocorticoid Receptor: Preliminary Findings in Healthy Adults. <i>PLoS ONE</i> , 2012, 7, e30148.	2.5	416
4	A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2015, 78, 240-248.	1.3	415
5	Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 35-48.	2.2	388
6	Association between Plasma IL-6 Response to Acute Stress and Early-Life Adversity in Healthy Adults. <i>Neuropsychopharmacology</i> , 2010, 35, 2617-2623.	5.4	378
7	Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study. <i>Biological Psychiatry</i> , 2005, 58, 355-363.	1.3	345
8	A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2005, 58, 364-373.	1.3	319
9	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>American Journal of Psychiatry</i> , 2020, 177, 391-410.	7.2	309
10	Childhood Maltreatment and Telomere Shortening: Preliminary Support for an Effect of Early Stress on Cellular Aging. <i>Biological Psychiatry</i> , 2010, 67, 531-534.	1.3	300
11	Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. <i>Neurosurgery Clinics of North America</i> , 2003, 14, 199-212.	1.7	284
12	Tryptophan Depletion During Continuous CSF Sampling in Healthy Human Subjects. <i>Neuropsychopharmacology</i> , 1998, 19, 26-35.	5.4	270
13	TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICE. <i>Depression and Anxiety</i> , 2012, 29, 587-596.	4.1	267
14	Sex differences in emotional and physiological responses to the Trier Social Stress Test. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2008, 39, 87-98.	1.2	258
15	Effect of childhood physical abuse on cortisol stress response. <i>Psychopharmacology</i> , 2011, 214, 367-375.	3.1	257
16	Interaction of Childhood Maltreatment with the Corticotropin-Releasing Hormone Receptor Gene: Effects on Hypothalamic-Pituitary-Adrenal Axis Reactivity. <i>Biological Psychiatry</i> , 2009, 66, 681-685.	1.3	254
17	Effect of Childhood Emotional Abuse and Age on Cortisol Responsivity in Adulthood. <i>Biological Psychiatry</i> , 2009, 66, 69-75.	1.3	233
18	A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. <i>Biological Psychiatry</i> , 2002, 51, 183-188.	1.3	232

#	ARTICLE	IF	CITATIONS
19	Childhood Parental Loss and Adult Hypothalamic-Pituitary-Adrenal Function. <i>Biological Psychiatry</i> , 2008, 63, 1147-1154.	1.3	221
20	Alterations of Mitochondrial DNA Copy Number and Telomere Length With Early Adversity and Psychopathology. <i>Biological Psychiatry</i> , 2016, 79, 78-86.	1.3	207
21	Network Mechanisms of Clinical Response to Transcranial Magnetic Stimulation in Posttraumatic Stress Disorder and Major Depressive Disorder. <i>Biological Psychiatry</i> , 2018, 83, 263-272.	1.3	193
22	Cerebrospinal Fluid Corticotropin-Releasing Factor and Perceived Early-Life Stress in Depressed Patients and Healthy Control Subjects. <i>Neuropsychopharmacology</i> , 2004, 29, 777-784.	5.4	180
23	Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. <i>Brain Stimulation</i> , 2015, 8, 787-794.	1.6	145
24	Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 637-643.	7.2	136
25	Efficacy of Continuation ECT and Antidepressant Drugs Compared to Long-Term Antidepressants Alone in Depressed Patients. <i>American Journal of Psychiatry</i> , 2000, 157, 1960-1965.	7.2	134
26	Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis. <i>American Journal of Psychiatry</i> , 2019, 176, 44-56.	7.2	122
27	The Clinical Correlates of Reported Childhood Sexual Abuse: An Association Between Age at Trauma Onset and Severity of Depression and PTSD in Adults. <i>Journal of Child Sexual Abuse</i> , 2010, 19, 156-170.	1.3	121
28	Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. <i>American Journal of Psychiatry</i> , 2018, 175, 873-886.	7.2	119
29	Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. <i>Revista Brasileira De Psiquiatria</i> , 2003, 25, 231-238.	1.7	117
30	A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1394-1401.	2.2	114
31	Adenosylmethionine (SAME) for Neuropsychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e656-e667.	2.2	110
32	Low-Intensity Transcranial Current Stimulation in Psychiatry. <i>American Journal of Psychiatry</i> , 2017, 174, 628-639.	7.2	105
33	Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. <i>Biological Psychiatry</i> , 2004, 56, 418-426.	1.3	103
34	Association of telomere length and mitochondrial DNA copy number in a community sample of healthy adults. <i>Experimental Gerontology</i> , 2015, 66, 17-20.	2.8	97
35	Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 637.	7.2	83
36	Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. <i>Journal of Affective Disorders</i> , 2020, 277, 65-74.	4.1	72

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. <i>Journal of Affective Disorders</i> , 2004, 79, 285-289.	4.1	71
38	61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. <i>Brain Stimulation</i> , 2017, 10, 847-849.	1.6	69
39	Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. <i>Psychoneuroendocrinology</i> , 2009, 34, 1208-1213.	2.7	63
40	Neuroimaging Mechanisms of Therapeutic Transcranial Magnetic Stimulation for Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 211-222.	1.5	62
41	Cortisol and ACTH responses to the Dex/CRH Test: Influence of temperament. <i>Hormones and Behavior</i> , 2008, 53, 518-525.	2.1	60
42	Childhood Parental Loss and Adult Psychopathology: Effects of Loss Characteristics and Contextual Factors. <i>International Journal of Psychiatry in Medicine</i> , 2008, 38, 329-344.	1.8	58
43	Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study. <i>Brain Stimulation</i> , 2016, 9, 251-257.	1.6	55
44	5â€Hz Transcranial Magnetic Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depression. <i>Journal of Traumatic Stress</i> , 2016, 29, 93-96.	1.8	51
45	Use of machine learning in predicting clinical response to transcranial magnetic stimulation in comorbid posttraumatic stress disorder and major depression: A resting state electroencephalography study. <i>Journal of Affective Disorders</i> , 2019, 252, 47-54.	4.1	51
46	Transcranial magnetic stimulation for treatment-resistant depression: Naturalistic treatment outcomes for younger versus older patients. <i>Journal of Affective Disorders</i> , 2017, 217, 42-47.	4.1	49
47	Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients â€“ A lifetime analysis. <i>PLoS ONE</i> , 2017, 12, e0186950.	2.5	47
48	Regional homogeneity and resting state functional connectivity: Associations with exposure to early life stress. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 247-253.	1.8	46
49	Exposure to childhood trauma is associated with altered n-back activation and performance in healthy adults: implications for a commonly used working memory task. <i>Brain Imaging and Behavior</i> , 2016, 10, 124-135.	2.1	45
50	Do obese depressed patients respond to topiramate? a retrospective chart review. <i>Journal of Affective Disorders</i> , 2002, 69, 251-255.	4.1	44
51	5â€Hz Repetitive transcranial magnetic stimulation for posttraumatic stress disorder comorbid with major depressive disorder. <i>Journal of Affective Disorders</i> , 2018, 235, 414-420.	4.1	44
52	Cerebrospinal fluid interleukin-6 in obsessiveâ€“compulsive disorder and trichotillomania. <i>Psychiatry Research</i> , 2002, 112, 257-262.	3.3	42
53	Social media recruitment for mental health research: A systematic review. <i>Comprehensive Psychiatry</i> , 2020, 103, 152197.	3.1	41
54	Cerebrospinal Fluid Corticotropin-Releasing Hormone in Healthy Humans: Effects of Yohimbine and Naloxone1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4138-4145.	3.6	40

#	ARTICLE	IF	CITATIONS
55	Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis. <i>Translational Psychiatry</i> , 2021, 11, 330.	4.8	40
56	Early life stress predicts thalamic hyperconnectivity: A transdiagnostic study of global connectivity. <i>Journal of Psychiatric Research</i> , 2016, 79, 93-100.	3.1	39
57	The relationship between individual alpha peak frequency and clinical outcome with repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD). <i>Brain Stimulation</i> , 2019, 12, 1572-1578.	1.6	39
58	A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder. <i>BMC Psychiatry</i> , 2019, 19, 13.	2.6	39
59	Training in the practice of noninvasive brain stimulation: Recommendations from an IFCN committee. <i>Clinical Neurophysiology</i> , 2021, 132, 819-837.	1.5	38
60	Individual alpha frequency proximity associated with repetitive transcranial magnetic stimulation outcome: An independent replication study from the ICON-DB consortium. <i>Clinical Neurophysiology</i> , 2021, 132, 643-649.	1.5	32
61	Open-Label Tiagabine Monotherapy for Major Depressive Disorder With Anxiety. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 66-71.	2.2	32
62	Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. <i>CNS Spectrums</i> , 2013, 18, 322-332.	1.2	31
63	Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans. <i>Neuropsychopharmacology</i> , 2003, 28, 339-347.	5.4	29
64	rTMS with a two-coil array: Safety and efficacy for treatment resistant major depressive disorder. <i>Brain Stimulation</i> , 2017, 10, 926-933.	1.6	29
65	Early life stress impacts dorsolateral prefrontal cortex functional connectivity in healthy adults: Informing future studies of antidepressant treatments. <i>Journal of Psychiatric Research</i> , 2014, 52, 63-69.	3.1	28
66	Neurostimulation in resistant depression. <i>Journal of Psychopharmacology</i> , 2006, 20, 35-40.	4.0	27
67	Updates on Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder. <i>Psychiatric Clinics of North America</i> , 2018, 41, 419-431.	1.3	25
68	Feasibility of Computerized Cognitive-Behavioral Therapy Combined With Bifrontal Transcranial Direct Current Stimulation for Treatment of Major Depression. <i>Neuromodulation</i> , 2019, 22, 898-903.	0.8	25
69	Mapping PTSD symptoms to brain networks: a machine learning study. <i>Translational Psychiatry</i> , 2020, 10, 195.	4.8	25
70	The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause. <i>Psychoneuroendocrinology</i> , 2020, 112, 104512.	2.7	24
71	Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder. <i>Brain Stimulation</i> , 2021, 14, 173-180.	1.6	24
72	Cognitive outcome after ventral capsule/ventral striatum stimulation for treatment-resistant major depression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 262-265.	1.9	23

#	ARTICLE	IF	CITATIONS
73	Resting EEG theta connectivity and alpha power to predict repetitive transcranial magnetic stimulation response in depression: A non-replication from the ICON-DB consortium. <i>Clinical Neurophysiology</i> , 2021, 132, 650-659.	1.5	23
74	Augmentation With Open-Label Atomoxetine for Partial or Nonresponse to Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1234-1238.	2.2	23
75	5Hz Repetitive transcranial magnetic stimulation to left prefrontal cortex for major depression. <i>Journal of Affective Disorders</i> , 2015, 186, 13-17.	4.1	22
76	Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression. <i>Frontiers in Psychiatry</i> , 2018, 9, 424.	2.6	18
77	Neurocognitive Effects of Repetitive Transcranial Magnetic Stimulation With a 2-Coil Device in Treatment-Resistant Major Depressive Disorder. <i>Journal of ECT</i> , 2018, 34, 258-265.	0.6	16
78	Network Functional Architecture and Aberrant Functional Connectivity in Post-Traumatic Stress Disorder: A Clinical Application of Network Convergence. <i>Brain Connectivity</i> , 2018, 8, 549-557.	1.7	16
79	Neuroimaging Correlates of Suicidality in Decision-Making Circuits in Posttraumatic Stress Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 44.	2.6	16
80	Predictors of response to synchronized transcranial magnetic stimulation for major depressive disorder. <i>Depression and Anxiety</i> , 2019, 36, 278-285.	4.1	16
81	NMDA-receptor agonist reveals LTP-like properties of 10-Hz rTMS in the human motor cortex. <i>Brain Stimulation</i> , 2021, 14, 619-621.	1.6	16
82	Effects of transcranial magnetic stimulation on anhedonia in treatment resistant major depressive disorder. <i>Brain and Behavior</i> , 2021, 11, e2329.	2.2	16
83	The Cellular Sequelae of Early Stress: Focus on Aging and Mitochondria. <i>Neuropsychopharmacology</i> , 2016, 41, 388-389.	5.4	15
84	Molecular markers of neuroendocrine function and mitochondrial biogenesis associated with early life stress. <i>Psychoneuroendocrinology</i> , 2020, 116, 104632.	2.7	15
85	Cervical vagus nerve stimulation for treatment-resistant depression. <i>Neurosurgery Clinics of North America</i> , 2003, 14, 275-282.	1.7	14
86	Service Expectations and Clinical Characteristics of Patients Receiving Psychiatric Emergency Services. <i>Psychiatric Services</i> , 2005, 56, 743-745.	2.0	14
87	Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. <i>Psychiatry Research</i> , 2008, 157, 123-129.	3.3	14
88	Transcranial direct current stimulation for unipolar depression and risk of treatment emergent mania: An updated meta-analysis. <i>Brain Stimulation</i> , 2019, 12, 1066-1068.	1.6	14
89	Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry. <i>Brain Stimulation</i> , 2022, 15, 326-336.	1.6	14
90	White matter integrity and functional predictors of response to repetitive transcranial magnetic stimulation for posttraumatic stress disorder and major depression. <i>Depression and Anxiety</i> , 2019, 36, 1047-1057.	4.1	13

#	ARTICLE	IF	CITATIONS
91	Identification of clinical features and biomarkers that may inform a personalized approach to rTMS for depression. <i>Personalized Medicine in Psychiatry</i> , 2019, 17-18, 4-16.	0.1	13
92	Safe Use of Repetitive Transcranial Magnetic Stimulation in Patients With Implanted Vagus Nerve Stimulators. <i>Brain Stimulation</i> , 2014, 7, 608-612.	1.6	12
93	Cerebrospinal fluid proteome evaluation in major depressive disorder by mass spectrometry. <i>BMC Psychiatry</i> , 2020, 20, 481.	2.6	11
94	Can early treatment response serve as a predictor of antidepressant outcome of repetitive Transcranial Magnetic Stimulation?. <i>Brain Stimulation</i> , 2020, 13, 420-421.	1.6	10
95	Translating Interventional Neuroscience to Suicide: It's About Time. <i>Biological Psychiatry</i> , 2021, 89, 1073-1083.	1.3	10
96	Pilot Testing of Peak Alpha Frequency Stability During Repetitive Transcranial Magnetic Stimulation. <i>Frontiers in Psychiatry</i> , 2018, 9, 605.	2.6	9
97	Peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation in treatment-resistant depression. <i>NeuroReport</i> , 2020, 31, 1121-1127.	1.2	9
98	Behavioral activation therapy during transcranial magnetic stimulation for major depressive disorder. <i>Journal of Affective Disorders</i> , 2018, 236, 101-104.	4.1	8
99	Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 262, 118-125.	4.1	8
100	Systematic review of preservation TMS that includes continuation, maintenance, relapse-prevention, and rescue TMS. <i>Journal of Affective Disorders</i> , 2022, 296, 79-88.	4.1	8
101	Large-scale EEG neural network changes in response to therapeutic TMS. <i>Brain Stimulation</i> , 2022, 15, 316-325.	1.6	8
102	Multimodal Elements of Suicidality Reduction After Transcranial Magnetic Stimulation. <i>Neuromodulation</i> , 2021, 24, 930-937.	0.8	7
103	A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. <i>Psychopharmacology</i> , 2011, 218, 371-379.	3.1	6
104	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 95-115.	0.8	6
105	Heart Rate Variability Responses to a Standardized Virtual Reality Exposure in Veterans with PTSD. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 271-280.	1.9	5
106	Repetitive Transcranial Magnetic Stimulation for depression relapse or recurrence: Naturalistic retreatment series outcomes. <i>Brain Stimulation</i> , 2019, 12, 1328-1329.	1.6	5
107	A case series describing orlistat use in patients on psychotropic medications. <i>Medicine and Health, Rhode Island</i> , 2004, 87, 375-7.	0.1	4
108	Effect of Previous Electroconvulsive Therapy on Subsequent Response to Transcranial Magnetic Stimulation for Major Depressive Disorder. <i>Neuromodulation</i> , 2020, 23, 393-398.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Dr McClintock and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 17lr11887a.	2.2	3
110	Mechanical Affective Touch Therapy for Anxiety Disorders: Effects on Resting State Functional Connectivity. <i>Neuromodulation</i> , 2022, , .	0.8	3
111	Do deviations from the 5 sessions per week schedule impact outcomes of transcranial magnetic stimulation for major depressive disorder?. <i>Brain Stimulation</i> , 2020, 13, 1491-1493.	1.6	2
112	The Future Is Now? Rapid Advances by Brain Stimulation Innovation. <i>American Journal of Psychiatry</i> , 2020, 177, 654-656.	7.2	2
113	Safety of rTMS in patients with intracranial metallic objects. <i>Brain Stimulation</i> , 2020, 13, 928-929.	1.6	2
114	Vagus nerve stimulation and deep brain stimulation for treatment resistant depression. <i>Medicine and Health, Rhode Island</i> , 2006, 89, 137, 140-1.	0.1	2
115	Mechanical Affective Touch Therapy for Anxiety Disorders: Feasibility, Clinical Outcomes, and Electroencephalography Biomarkers From an Open-Label Trial. <i>Frontiers in Psychiatry</i> , 2022, 13, 877574.	2.6	2
116	Transient aphasia induced by intermittent theta burst stimulation. <i>Brain Stimulation</i> , 2020, 13, 941-942.	1.6	1
117	A preliminary investigation of childhood anxiety/depressive symptomatology and working memory across multiple units of analysis. <i>Psychiatry Research</i> , 2021, 298, 113786.	3.3	1
118	Effects of single-dose L-theanine on motor cortex excitability. <i>Clinical Neurophysiology</i> , 2021, 132, 2062-2064.	1.5	1
119	The Efficacy of Transcranial Magnetic Stimulation for Major Depression: A Review of the Evidence. <i>Psychiatric Annals</i> , 2014, 44, 284-292.	0.1	1
120	Immune Consequences of Early Life Stress: Relationship to Chronic Pain Syndromes. , 2013, , 237-253.		0
121	Do bipolar disorder soft signs impact outcomes following Transcranial Magnetic Stimulation (TMS) therapy for depression?. <i>Journal of Affective Disorders</i> , 2019, 245, 237-240.	4.1	0
122	SAT-737 Low-Dose Testosterone Augmentation for Treatment-Resistant Depression in Women: An 8-Week, Two-Site, Randomized, Placebo-Controlled Study. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
123	Audio-Guided Mindfulness Meditation During Transcranial Magnetic Stimulation Sessions for the Treatment of Major Depressive Disorder: A Pilot Feasibility Study. <i>Frontiers in Psychology</i> , 2021, 12, 678911.	2.1	0
124	Advances in Neurostimulation for Depression: Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Vagus Nerve Stimulation, and Deep Brain Stimulation. <i>Medical Psychiatry</i> , 2009, , 166-185.	0.2	0
125	Transcranial Magnetic Stimulation. , 2014, , 1-6.		0
126	Dr McClintock and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 17lr11851a.	2.2	0

#	ARTICLE	IF	CITATIONS
127	MON-449 Serum Neuroactive Steroid Levels in Postmenopausal Women with Treatment-Resistant Major Depressive Disorder. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
128	The COBRE Center for Neuromodulation (CCN) at Butler Hospital: Clinical-Translational Research in Human Brain Stimulation. <i>Rhode Island Medical Journal</i> (2013), 2021, 104, 30-33.	0.2	0
129	Transdiagnostic Symptom Subtypes to Predict Response to Therapeutic Transcranial Magnetic Stimulation in Major Depressive Disorder and Posttraumatic Stress Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 224.	2.5	0